Werewolf Therapeutics to Attend Jefferies Global Healthcare Conference
Watertown, Mass., May 30, 2024 – Werewolf Therapeutics, Inc. (Nasdaq: HOWL), a pioneering biopharmaceutical company focused on developing conditionally activated therapeutics to enhance the body's immune system for cancer treatment, announced notable participation in the Jefferies Global Healthcare Conference. The event will be held from June 4-6, 2024, in New York City, New York.
Key Participants and Schedule:
Daniel J. Hicklin, Ph.D., President and CEO of Werewolf, along with Randi Isaacs, M.D., Chief Medical Officer, will engage in a fireside chat at the conference on June 6 at 1:00 PM ET.
Webcast Information:
A live webcast of the event will be available, and an archived replay will be accessible for approximately 90 days post-conference.
About Werewolf Therapeutics:
Werewolf Therapeutics is at the forefront of biopharmaceutical innovation. The company specializes in creating therapeutics that harness the body's immune system to treat cancer and other immune-mediated conditions. Their proprietary PREDATOR™ platform is central to their work, enabling the design of conditionally activated molecules that stimulate both adaptive and innate immunity, addressing the shortcomings of traditional proinflammatory immune therapies.
Key Technologies and Products:
The company's INDUKINE™ molecules are designed to remain inactive in peripheral tissues but activate selectively in the tumor microenvironment. This strategic activation aims to boost the efficacy of immune responses while minimizing systemic side effects.
Leading Product Candidates:
- WTX-124: A conditionally activated Interleukin-2 (IL-2) INDUKINE molecule for the treatment of solid tumors. It is being advanced both as a single agent and in combination with immune checkpoint inhibitors.
- WTX-330: A conditionally activated Interleukin-12 (IL-12) INDUKINE molecule, also aimed at treating solid tumors and potentially Non-Hodgkin Lymphoma. This molecule is being developed for use as a single agent.
Werewolf Therapeutics aims to push forward WTX-124 and WTX-330 through various clinical trials to establish their efficacy across multiple tumor types.
In summary, Werewolf Therapeutics' participation in the Jefferies Global Healthcare Conference highlights their commitment to advancing innovative cancer treatments. Their focus on conditionally activated therapeutics represents a significant step forward in enhancing immune responses within the tumor microenvironment, offering new hope for effective cancer therapies.
How to obtain the latest research advancements in the field of biopharmaceuticals?
In the Synapse database, you can keep abreast of the latest research and development advances in drugs, targets, indications, organizations, etc., anywhere and anytime, on a daily or weekly basis. Click on the image below to embark on a brand new journey of drug discovery!
